New CRISPR Fight: Old Friends Intellia, Caribou in License Dispute

An epic legal battle over CRISPR-Cas9 genome editing ended last year. But another one, smaller in scope and involving two long-time CRISPR allies, has quietly begun.

Last October, Intellia Therapeutics (NASDAQ: NTLA) began an arbitration proceeding against Caribou Biosciences, alleging in a recent regulatory filing that its longstanding partner had broken the terms of a key license between the two companies.

Caribou, of Berkeley, CA, was founded in 2011 to house the CRISPR-Cas9 intellectual property generated in the University of California, Berkeley, lab of Jennifer Doudna. The researcher and her colleagues helped turn an obscure bacterial defense system into a… Read more »





READ  Agilent Acquires Cell Analysis Tools Developer ACEA Biosciences

Leave a Reply